Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BONDUELLE Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number: 447 250 044...
-
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for...
-
PRESS RELEASE – FEBRUARY 26, 2026 2025 Full-Year Results In 2025, Wendel accelerated the transformation of its business model: €1591 million of proforma FRE generated by Wendel Investment...
-
Wolters Kluwer, a global leader in professional information solutions, software and services, today releases its full-year 2025 results.
-
PRESS RELEASE Courbevoie, France – February 25, 2026 Sector-leading organic revenue growth of 6.5% in FY 2025 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued...
-
Hyderabad, Feb. 24, 2026 (GLOBE NEWSWIRE) -- According to a newly published report by Mordor Intelligence, inspection drones market size is expanding rapidly, valued at USD 11.75 billion in 2025 and...
-
VANCOUVER, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) ("Ero" or the “Company”) is pleased to announce results of the Preliminary Economic Assessment...
-
Los Angeles, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Last year, judges from across the country, 3 attorneys general, and plaintiffs' attorneys descended on the J.W. Marriott in Los Angeles for the...
-
AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- NetworkNewsWire Editorial Coverage: Healthcare real estate investment trusts (REITs) have emerged as one of the more resilient and structurally...
-
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate...